Skip to content

Study · Non-randomized trial · n = 55 · 1994

3 results

Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection.

Vercellini P, Trespidi L, Bramante T, Panazza S, Mauro F, Crosignani PG

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics1 Jun 1994Cited by 18 (Europe PMC)

PMID7926242 (opens in a new tab)DOI10.1016/0020-7292(94)90248-8 (opens in a new tab)PepBankPUB-07926242
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients undergoing endometrial resection, distension medium deficit was lower after goserelin than in controls (511 +/- 196 versus 647 +/- 245 ml, P = 0.03).

    In plain wordsIn patients undergoing endometrial resection, fluid deficit was lower after goserelin than in controls.

    Peptide
    Goserelin
    Outcome
    DecreaseDistension medium deficit
    Study

    n = 55

    Comparator
    Resection during proliferative phase without goserelin pretreatment
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 monthsAs given in this study (human).

    Measurements

    Mean distension medium deficit
    511 ml
    goserelin pretreatment cases, SD 196
    Mean distension medium deficit
    647 ml
    controls, SD 245

    Source sentences

    Summary
    In the cases, the mean distension medium deficit +/- S.D. was 511 +/- 196 ml versus 647 +/- 245 ml in controls (P = 0.03), and the operating times were, respectively, 14 +/- 4 versus 18 +/- 5 min (P = 0.002).
    1 context sentence
    Summary · context
    Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients undergoing endometrial resection, operating time was shorter after goserelin than in controls (14 +/- 4 versus 18 +/- 5 min, P = 0.002).

    In plain wordsIn patients undergoing endometrial resection, operations were shorter after goserelin than in controls.

    Peptide
    Goserelin
    Outcome
    DecreaseOperating time
    Study

    n = 55

    Comparator
    Resection during proliferative phase without goserelin pretreatment
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 monthsAs given in this study (human).

    Measurements

    Mean operating time
    14 min
    goserelin pretreatment cases, SD 4
    Mean operating time
    18 min
    controls, SD 5

    Source sentences

    Summary
    In the cases, the mean distension medium deficit +/- S.D. was 511 +/- 196 ml versus 647 +/- 245 ml in controls (P = 0.03), and the operating times were, respectively, 14 +/- 4 versus 18 +/- 5 min (P = 0.002).
    1 context sentence
    Summary · context
    Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls).
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients undergoing endometrial resection, operating conditions were excellent or good in 64% after goserelin versus 27% of controls (P = 0.02).

    In plain wordsIn patients undergoing endometrial resection, good operating conditions were more frequent after goserelin than in controls.

    Peptide
    Goserelin
    Outcome
    IncreaseExcellent or good operating conditions
    Study

    n = 55

    Comparator
    Resection during proliferative phase without goserelin pretreatment
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 monthsAs given in this study (human).

    Measurements

    Operating conditions excellent or good
    64%
    goserelin pretreatment cases
    Operating conditions excellent or good
    27%
    controls

    Source sentences

    Summary
    The intrauterine operating conditions were considered excellent or good in 64% of the cases versus 27% of the controls (chi 2 = 5.60, P = 0.02).
    1 context sentence
    Summary · context
    Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.